Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventiv...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Siddiqui, M. Arshad Schmidt, Darby Miller, Tom Marineau, Jason J Leblanc, Melissa Gray, Nathanael Sprott, Kevin Bradley, Michael Roy, Stephanie Ciblat, Stephane Zhang, Tinghu Winter, Dana K Moore, Joel Kabro, Anzhelika |
| description | The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US10906889B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US10906889B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US10906889B23</originalsourceid><addsrcrecordid>eNrjZLAMyM-pTK5MzslMVsjMy8hMyizJLypWyE9TAAvm6aakFqTmpaTmlShkZ-YlFqcqmCtoOLt4m2vyMLCmJeYUp_JCaW4GRTfXEGcP3dSC_PjU4oLE5NS81JL40GBDA0sDMwsLSycjY2LUAADpOi3D</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)</title><source>esp@cenet</source><creator>Siddiqui, M. Arshad ; Schmidt, Darby ; Miller, Tom ; Marineau, Jason J ; Leblanc, Melissa ; Gray, Nathanael ; Sprott, Kevin ; Bradley, Michael ; Roy, Stephanie ; Ciblat, Stephane ; Zhang, Tinghu ; Winter, Dana K ; Moore, Joel ; Kabro, Anzhelika</creator><creatorcontrib>Siddiqui, M. Arshad ; Schmidt, Darby ; Miller, Tom ; Marineau, Jason J ; Leblanc, Melissa ; Gray, Nathanael ; Sprott, Kevin ; Bradley, Michael ; Roy, Stephanie ; Ciblat, Stephane ; Zhang, Tinghu ; Winter, Dana K ; Moore, Joel ; Kabro, Anzhelika</creatorcontrib><description>The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.</description><language>eng</language><subject>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210202&DB=EPODOC&CC=US&NR=10906889B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210202&DB=EPODOC&CC=US&NR=10906889B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Siddiqui, M. Arshad</creatorcontrib><creatorcontrib>Schmidt, Darby</creatorcontrib><creatorcontrib>Miller, Tom</creatorcontrib><creatorcontrib>Marineau, Jason J</creatorcontrib><creatorcontrib>Leblanc, Melissa</creatorcontrib><creatorcontrib>Gray, Nathanael</creatorcontrib><creatorcontrib>Sprott, Kevin</creatorcontrib><creatorcontrib>Bradley, Michael</creatorcontrib><creatorcontrib>Roy, Stephanie</creatorcontrib><creatorcontrib>Ciblat, Stephane</creatorcontrib><creatorcontrib>Zhang, Tinghu</creatorcontrib><creatorcontrib>Winter, Dana K</creatorcontrib><creatorcontrib>Moore, Joel</creatorcontrib><creatorcontrib>Kabro, Anzhelika</creatorcontrib><title>Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)</title><description>The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.</description><subject>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAMyM-pTK5MzslMVsjMy8hMyizJLypWyE9TAAvm6aakFqTmpaTmlShkZ-YlFqcqmCtoOLt4m2vyMLCmJeYUp_JCaW4GRTfXEGcP3dSC_PjU4oLE5NS81JL40GBDA0sDMwsLSycjY2LUAADpOi3D</recordid><startdate>20210202</startdate><enddate>20210202</enddate><creator>Siddiqui, M. Arshad</creator><creator>Schmidt, Darby</creator><creator>Miller, Tom</creator><creator>Marineau, Jason J</creator><creator>Leblanc, Melissa</creator><creator>Gray, Nathanael</creator><creator>Sprott, Kevin</creator><creator>Bradley, Michael</creator><creator>Roy, Stephanie</creator><creator>Ciblat, Stephane</creator><creator>Zhang, Tinghu</creator><creator>Winter, Dana K</creator><creator>Moore, Joel</creator><creator>Kabro, Anzhelika</creator><scope>EVB</scope></search><sort><creationdate>20210202</creationdate><title>Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)</title><author>Siddiqui, M. Arshad ; Schmidt, Darby ; Miller, Tom ; Marineau, Jason J ; Leblanc, Melissa ; Gray, Nathanael ; Sprott, Kevin ; Bradley, Michael ; Roy, Stephanie ; Ciblat, Stephane ; Zhang, Tinghu ; Winter, Dana K ; Moore, Joel ; Kabro, Anzhelika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US10906889B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>Siddiqui, M. Arshad</creatorcontrib><creatorcontrib>Schmidt, Darby</creatorcontrib><creatorcontrib>Miller, Tom</creatorcontrib><creatorcontrib>Marineau, Jason J</creatorcontrib><creatorcontrib>Leblanc, Melissa</creatorcontrib><creatorcontrib>Gray, Nathanael</creatorcontrib><creatorcontrib>Sprott, Kevin</creatorcontrib><creatorcontrib>Bradley, Michael</creatorcontrib><creatorcontrib>Roy, Stephanie</creatorcontrib><creatorcontrib>Ciblat, Stephane</creatorcontrib><creatorcontrib>Zhang, Tinghu</creatorcontrib><creatorcontrib>Winter, Dana K</creatorcontrib><creatorcontrib>Moore, Joel</creatorcontrib><creatorcontrib>Kabro, Anzhelika</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Siddiqui, M. Arshad</au><au>Schmidt, Darby</au><au>Miller, Tom</au><au>Marineau, Jason J</au><au>Leblanc, Melissa</au><au>Gray, Nathanael</au><au>Sprott, Kevin</au><au>Bradley, Michael</au><au>Roy, Stephanie</au><au>Ciblat, Stephane</au><au>Zhang, Tinghu</au><au>Winter, Dana K</au><au>Moore, Joel</au><au>Kabro, Anzhelika</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)</title><date>2021-02-02</date><risdate>2021</risdate><abstract>The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US10906889B2 |
| source | esp@cenet |
| subjects | ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
| title | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A31%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Siddiqui,%20M.%20Arshad&rft.date=2021-02-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS10906889B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |